Trial Profile
Study evaluating pathomechanism and radical formation associated with Sorafenib, Sunitinib and Capecitabine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Cancer
- Focus Adverse reactions
- 01 Sep 2018 Results published in the Anticancer Research
- 07 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology